Properties
What is it?
International Name - Paracetamolum International and Chemical Name: Paracetamol; para-acetaminophenol. Basic Physical-Chemical Properties: Transparent, viscous, pink, sweet-tasting syrup with a characteristic raspberry aroma. Composition: 100 ml of syrup contains 2.4 g of paracetamol. Excipients: Propylene glycol, glycerin, ethyl alcohol, sorbitol powder, nipagin, nipasol, raspberry food flavoring essence, C 121 dye (light red-carmine color) and purified water. Dosage Form: Syrup Pharmacological Group: Anti-inflammatory, analgesic, and antipyretic agent. Indications: Pain syndrome of various origins, mild to moderate intensity (headache, toothache, neuralgia, myalgia; teething pain, as well as pain from injuries, burns, pharyngitis, rheumatic pains). Also for fever caused by infectious-inflammatory diseases, and childhood viral infections. Dosage and Administration: The preparation is administered orally. For children aged 6 months to 1 year: 2.5-5 ml of syrup (0.5-1 teaspoon). For children aged 1 to 3 years: 5-7.5 ml of syrup (1-1.5 teaspoons). For children aged 3 to 6 years: 7.5-10 ml (1.5-2 teaspoons). For children aged 6 to 12 years: 10-15 ml (2-3 teaspoons). For children over 12 years of age: 15-25 ml (3-4 teaspoons). Frequency of administration: 3-4 times per day, with an interval of at least 4 hours between each dose. Side Effects: In case of hypersensitivity to paracetamol, nausea, epigastric pain, and allergic reactions (skin rash, itching, urticaria, Quincke's edema) may occur. Overdose of the recommended dose of syrup may lead to the development of the following side effects: hemolytic anemia, thrombocytopenic purpura, methemoglobinemia, agranulocytosis. Prolonged administration at doses exceeding therapeutic levels may cause hepatotoxic effects. Contraindications: Hypersensitivity to paracetamol, severe impairment of liver and kidney function, glucose-6-phosphatase dehydrogenase deficiency, blood diseases, children under 6 months of age. Interactions with Other Medicinal Products: Patients using barbiturates and tricyclic antidepressants may experience an increased half-life of paracetamol during its use. Prolonged use of anticonvulsant drugs leads to increased activity of liver enzymes, which enhances the "first-pass" effect in the liver and leads to increased clearance of the drug. This may hinder the achievement of therapeutic levels of paracetamol concentration in the blood.